Tillkännagivande • Apr 12

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionally, the Company’s Board of Directors unanimously determined not to proceed with a second return of capital under the October 31, 2023 Anson Funds and Cable Car Capital cooperation agreement in order to conserve resources and align strategic investment, and thereby extend the Company’s operational runway. As previously disclosed, the Company’s October 31, 2023 Cooperation Agreement with stockholders, including Anson Funds and Cable Car Capital, provided that a potential second return of capital could be authorized by the Board under certain circumstances as outlined in that agreement, subject to the exercise of the Board’s fiduciary duties. Since data reported from Cohort 1 of the Phase 1b study exceeded a criterion for the potential second return of capital stated in the Agreement, the trigger for a return of capital was not met. The Board further unanimously determined, after deciding not to proceed with Cohort 2, that in the exercise of its fiduciary duties under applicable law, and in light of its views on what path is in the best interests of the Company’s stockholders, the Company would not proceed with any additional potential return of capital as permitted under the Cooperation Agreement. The strategy unanimously approved by the MEI Board of Directors provides for advancing clinical development of voruciclib, an investigational selective oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, to new value inflection points by the end of calendar year 2025 and for enabling a new formulation of ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation (“OXPHOS”). The plan builds on encouraging recently reported voruciclib clinical data and ME-344 data separately reported . Specifically with respect to voruciclib, the development objective is to optimize voruciclib for a Phase 3 study in combination with venetoclax (Venclexta®) in patients with relapsed and refractory (“R/R”) acute myeloid leukemia (“AML”). Under the plan, the ongoing voruciclib development strategy will be guided by future clinical trial results and applicable regulatory authority advice. Subject to positive Phase 1 data later this year, MEI plans to amend the ongoing Phase 1 study to add a Phase 2 study arm, with enrollment in the Phase 2 arm anticipated to begin in 2025. This is anticipated to generate Phase 2 data by the end of 2025. Contingent on the success of the Phase 1/2 study, MEI plans to have the program ready to initiate a Phase 3 registration trial during 2026. With regards to ME-344, the plan is to develop a new formulation for further clinical development to better leverage the opportunity to advance a novel approach to inducing synthetic lethality in tumors in combination with VEGF inhibitors such as bevacizumab (Avastin®). The Company has already initiated research and development activity of the new formulation with encouraging results, with the goal of increasing biological activity, improving convenience of administration and increasing commercial opportunity. Interrupting ME-344 clinical activity and developing a new formulation will immediately reduce ME-344 expenditures. The Company recently reported initiation of enrollment in an expansion cohort of the ongoing Phase 1 study evaluating voruciclib plus venetoclax (Venclexta®), a B-cell lymphoma 2 (“BCL2”) inhibitor, in R/R AML. The decision to open the expansion cohort was based on encouraging initial data demonstrating anti-leukemic activity, including complete responses in heavily pretreated patients. Additionally, at doses of 100 mg or more, initial results from correlative biomarker assay analyses of available samples from patients treated with the combination demonstrated anticipated decreases of myeloid leukemia cell differentiation protein (“Mcl-1”), including a greater decrease in Mcl-1 at higher doses. Reductions in Mcl-1 are consistent with the known mechanism of action of CDK9. Further, there was no evidence of overlapping toxicity with venetoclax and no dose limiting toxicities were observed. Increasingly, venetoclax is being used as a standard treatment in patients with AML, but salvage therapy after venetoclax failure is common and yields limited benefit; only about 10% of patients respond to salvage therapy after venetoclax failure, representing a significant need for patients with AML. While mutation specific therapies, such as FLT3, IDH, and menin inhibitors, may be used in patients with such mutations, the majority of patients with AML do not have therapeutically actionable mutations. Thus, inhibition of CDK9 is a mutation agnostic therapeutic opportunity across the majority of patients with R/R AML, representing an addressable patient population larger than that of any mutation specific therapy. As separately reported, based on initial study results, 25% of evaluable patients with relapsed metastatic colorectal cancer (“mCRC”) enrolled in Cohort 1 of the ongoing Phase 1b study evaluating ME-344 in combination with bevacizumab (Avastin®) reached a predetermined 16-week progression free survival (“PFS”) threshold, exceeding the 20% threshold set in the Clinical Study Protocol. Patients were heavily pretreated and had failed standard therapies for their disease. The combination was also observed to have a generally well-tolerated safety profile. The recently reported data represent new clinical support of the potential of ME-344 in combination with VEGF inhibitors such as bevacizumab to induce synthetic lethality in tumors; this is a novel therapeutic strategy to potentially provide benefit to patients in a well-tolerated manner. Further, there is a significant medical need to provide patients with colorectal cancer new treatment options in light of the fact that deaths from this disease are a leading cause of cancer-related deaths in the U.S. and given that the incidence of colorectal cancer is increasing among those under 55. While the threshold was met to proceed to Cohort 2, the Company believes the best approach to meet the need of patients with mCRC, and potentially patients with other cancers where VEGF inhibitors are standard-of-care, is to continue to advance ME-344 via development of a new formulation, building upon the ME-344 results to date. The Company believes that development of a new formulation represents the optimal approach to leveraging the potential of the program and the novel therapeutic strategy to induce synthetic lethality in tumors via the combination.

Räntetäckningsgrad	n/a
Kontanter	US$7.54m
Eget kapital	US$56.84m
Summa skulder	US$952.00k
Totala tillgångar	US$57.79m

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/06/11 22:41
Aktiekurs vid dagens slut	2026/06/11 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/06/30

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

Analytiker	Institution
Stephen V. Byrne	BofA Global Research
Leah Rush Cann	Brookline Capital Markets
Daniel Brims	Cantor Fitzgerald & Co.

Lite Strategy Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 4/6

Viktig information

Nya uppdateringar om finansiell hälsa

Will Lite Strategy (NASDAQ:LITS) Spend Its Cash Wisely?

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Recent updates

Will Lite Strategy (NASDAQ:LITS) Spend Its Cash Wisely?

New minor risk - Insider selling

Insider recently sold US$946k worth of stock

New major risk - Financial position

Lite Strategy, Inc. (NasdaqCM:LITS) announces an Equity Buyback for $25 million worth of its shares.

New minor risk - Market cap size

New major risk - Share price stability

New major risk - Shareholder dilution

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

MEI Pharma, Inc. announced that it has received $99.999401 million in funding from GSR, Litecoin Foundation Ltd., Mozayyx Management LLC, RLH Capital, LLC, Delta Blockchain Fund LP, CoinFund LLC

MEI Pharma, Inc. Announces Board Changes

New minor risk - Share price stability

MEI Pharma, Inc., Annual General Meeting, Jan 30, 2025

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Consensus revenue estimates increase by 61%

Price target decreased by 12% to US$2.27

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Increases to CEO Compensation Might Be Put On Hold For Now at MEI Pharma, Inc. (NASDAQ:MEIP)

Price target decreased to US$2.90

Consensus revenue estimates increase by 26%

Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)

Price target increased to US$5.83

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

Consensus forecasts updated

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.81

We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash Wisely

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 11%

Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue Forecasts

No longer forecast to breakeven

MEI Pharma: Another PI3K Delta Progressing To The FDA

Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) Estimates

Consensus revenue estimates fall to US$38.1m

Price target increased to US$10.89

Independent Non Executive Director Kevan Clemens has left the company

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021)

We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn Rate

Price target increased to US$11.11

Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020)

Forecast to breakeven in 2024

Consensus revenue estimates fall to US$18.3m

Third quarter 2021 earnings released: US$0.28 loss per share (vs US$0.041 loss in 3Q 2020)

Independent Non-Executive Director notifies of intention to sell stock

The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their Holding

Independent Non-Executive Director recently sold US$101k worth of stock

New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)

Analysts update estimates

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020)

Analys av finansiell ställning